INTRODUCTION
Congenital cardiovascular malformations (CVMs) are among the most common of all medically significant birth defects and are a leading contributor to infant mortality in the United States. 1 Yet, the cause of these malformations is unknown in B85-90% of cases. 2, 3 Several large population-based studies estimate the prevalence of CVMs to range from 3 to 6 cases per 1000 live births. [4] [5] [6] The birth prevalence for severe CVMs in other studies is reported to be B1.5 cases per 1000 live births. 7, 8 Despite a wealth of information on the developmental pathways that operate during normal cardiogenesis, only a limited number of genes have been identified in which disease-causing mutations are associated with CVMs. Chromosomal abnormalities including trisomy 18, trisomy 13, Turner syndrome, Down syndrome and DiGeorge syndrome account for B10% of all cases of CVMs, 9 whereas another 3-5% of cases are caused by single gene disorders including CHARGE syndrome, Noonan syndrome and Holt-Oram syndrome. 10, 11 Estimating the fraction with a syndrome or genetic condition is challenging, although it can be approximated from the population-based Baltimore-Washington Infant Study in which nearly 17% of infants with a CVM had an identifiable syndrome. 3 The copy number variations (CNVs) resulting from instability of regional genomic architecture 12 are an important cause of CVMs 13 such as DiGeorge syndrome (22q11.2 deletion) 14 and Williams syndrome (7q11.23 deletion). 15 Other genomic disorders associated with CVMs include Smith-Magenis syndrome, 16 17q21.3 microdeletion syndrome 17 and 17q23.1q23.2 recurrent microdeletion syndrome. 18 These genomic disorders affect several contiguous genes, but often as exemplified by the TBX1 gene in 22q11del syndrome 19 and ELN in Williams syndrome, 20 a single gene is thought to be the major factor in causing the cardiovascular developmental defects because of haploinsufficiency.
For genes known to cause CVMs, there is typically variable expressivity, and extensive allelic heterogeneity. Currently, a working model for the genetic architecture of CVMs involves both rare and common variants, possibly with interaction of multiple genes and gene-environment interactions. 21 Rare variants are known to cause CVMs 22 and if these account for the major fraction of cases, the high frequency of CVMs could be explained by the large number of genes that play a role in normal cardiac development, called the 'large mutational target' hypothesis. 21, 23 We designed this study, to define critical regions within both novel and established genome structural variations likely to be important for human cardiac patterning. To establish a genome-wide schema of minimal critical regions encompassing haploinsufficient/dosage-sensitive genes in CVMs, a large pediatric cohort with extracardiac anomalies (ECAs) and normal cardiac studies was selected as controls for the study. We predicted that a genome-wide comparative analysis of cases and affected controls for segmental aneusomies would delineate a global signature of critical regions that are specific to cases.
MATERIALS AND METHODS Cases
The study was approved by the Institutional Review Board of the Baylor College of Medicine in Houston, Texas. The discovery set of 203 unrelated patients (BCM1 cohort) comprised 104 Hispanic/Latino Americans and 99 non-Hispanic patients of European descent, all evaluated at Texas Children's Hospital (TCH) in Houston, Texas. The cases included 104 males and 99 females, with a mean age of 3.0 years (0-18 years). All cases in this cohort were assessed by cardiologists, neurologists and/or dysmorphologists at TCH between January 2008 and July 2010. The echocardiographic diagnoses were used to classify cases according to the scheme of Botto et al 24 and encompassed eight categories: left ventricular outflow tract obstructive defects (LVOTOs, n ¼ 30), right ventricular outflow tract obstructive defects (RVOTOs, n ¼ 26), septal defects (n ¼ 54), atrioventricular septal defects (AVSDs, n ¼ 3), anomalous pulmonary venous return (APVR, n ¼ 4), conotruncal defects (n ¼ 29), heterotaxy (n ¼ 14) and complex (n ¼ 17) anomalies (Supplementary Figure 1) . The complex category included patients with multiple cardiac anomalies, L-transposition of great arteries (L-TGA) with RVOTOs, L-TGA plus LVOTOs, single ventricle or double-inlet left ventricle type with either d-or l-malposed great arteries. Individuals with dilated aortic root (n ¼ 11) and cardiomyopathy (n ¼ 15) were additionally included if there were no known molecular diagnoses. Those with patent ductus arteriosus (PDA), patent foramen ovale (PFO) and arrhythmias were excluded from the study. All cases were affected with ECAs, unexplained developmental delay and/or facial dysmorphisms (Supplementary Table 1 ). Of the 203 cases in the BCM1 cohort, 159 (78%) had renal ultrasound study, performed for ECA evaluation. Normal results were confirmed in 107 (67%) cases. Renal findings observed in the other 52 cases (33%) included hydronephrosis, unilateral renal agenesis, crossed renal ectopia and nephrocalcinosis. Brain imaging including cranial ultrasound, magnetic resonance imaging or CT scan were completed in 158/203 cases (B78%). Of these, 83 (52%) were normal studies. The abnormal findings observed in 75 cases (48%) are detailed in Supplementary Table 1 .
The second cohort consisted of 511 unrelated pediatric patients, also evaluated at TCH (BCM2 cohort). This group consisted of approximately equal numbers of Hispanic/Latino Americans and non-Hispanic patients of European descent. Cardiac diagnoses were confirmed by echocardiography in all cases. The subjects were similarly classified according to Botto et al 24 ( Supplementary Figure 2) Figure 3) . Both control cohorts had similar rates of ECAs, with or without unexplained developmental delay, and/or facial dysmorphisms (Supplementary Table 2 ). They were composed of approximately equal number of non-Hispanic Caucasians and Hispanic/Latino Americans, between the ages of 0 and 18 years. Both the first and second control sets were matched for age and ethnicity with the cases, as illustrated by the principal component analysis utilizing 10 000 oligonucleotides involving polymorphic loci (Supplementary Figure 4) . Using controls who had ECAs but were not affected with CVMs has several advantages that improve the specificity of the analysis, when a genomic region is a candidate to cause cardiac malformations: (1) all cases and controls came from the same clinic-based cohort; (2) were well matched for age and (3) ethnic background; (4) all studies for cases and controls were performed with similar Agilent technology; and were (5) analyzed with an identical segmentation statistical method, confirmed by a (6) large number of confirmatory observations using orthogonal technology; (7) all assays were performed on freshly isolated peripheral blood lymphocytes; and finally (8) the specificity of the CNV association with cardiac malformations makes it more likely that genes would be ascertained with specific cardiac development functions within this group of conditions.
To exclude the possibility of ascertaining polymorphic CNVs, Illumina genotypes of 2024 pediatric subjects from Children's Hospital of Philadelphia (CHOP) Control CNV Study, dbGaP Study Accession: phs000199.v1.p1 were also obtained for comparison from the Database of Genotypes and Phenotypes (dbGAP) found at http://www.ncbi.nih.gov.ezproxyhost.library.tmc.edu/gap.
All 203 cases (BCM1 cohort) and 872 controls were studied with customized 105k genome-wide arrays, using array comparative genomic hybridization (CGH) with B105 000 oligonucleotides covering the whole genome at an average resolution of 30 kb, with denser coverage at disease loci. The array was designed by Baylor Medical Genetics Laboratories and manufactured by Agilent Technology (Santa Clara, CA, USA; http://www.bcm.edu/geneticlabs/ cma/tables.html). [25] [26] [27] In the second cohort, the cases and controls were studied by either 44k, 105k or 180k oligonucleotide arrays on similar Agilent platform and including the 55 CNVs identified in the discovery set. Peripheral blood samples from the subjects were submitted to the Baylor Medical Genetics Laboratories. DNA was extracted from whole blood using the Puregene DNA Blood Kit (Gentra, Minneapolis, MN, USA) according to the manufacturer's instructions. Data analysis methods are included in the Supplementary Text.
RESULTS

CNVs in cases
Analysis of the 105k custom Agilent array data from BCM1 cohort including 203 subjects with CVMs plus ECAs detected a total of 547 CNVs (excluding Y chromosome, 276 copy number gains and 271 copy number losses), ranging from 54 kb to 36 Mb in size. Of these CNVs, 334 (61%) had Z93% overlap with copy number polymorphisms in the human genome, based on DGV. Large cytogenetic aberrations including unbalanced rearrangements were observed in 11/203 (3.9%) cases (Table 1) .
Multiple CNVs known to be associated with syndromic CVMs were observed, including 22q11.2 loss involving the DiGeorge critical region, seen in 7/203 cases, 7q11.23 loss corresponding to the Williams-Beuren syndrome (WBS) critical region, observed in 5/203 cases, and 16p13.11 gain including MYH11, 28 observed in 2/203 cases. Other rare genomic disorders in this cohort observed as singleton events included 1q21.1 recurrent microduplication, 22q11.1-q11.2 gain associated with Cat-Eye syndrome (CES), 17p13.3 loss corresponding to Miller-Dieker lissencephaly syndrome, 17p11.2 loss seen in Smith-Magenis syndrome and 17p11.2 reciprocal gain, observed in Potocki-Lupski syndrome (Table 1) .
We further compared cases with age-and ethnicity-matched controls to identify novel rare variants, observed in 203 cases but none in controls. Considering both known and novel CNVs, we identified 55 variants that were 450 kb, had DGV overlap of r75%, contained at least one known gene and were not present in the 872 controls (Table 2 ). Of these, 44 (80%) were singleton events. The CNVs included 1p36.33-p36.32 loss, corresponding to 1p36 microdeletion syndrome, observed in 4/203 cases and 0/872 controls. The 8p23.1 loss encompassing GATA4 and corresponding to 8p23.1 deletion syndrome was observed as a singleton event, not seen in 872 controls. The 22q11.2 loss corresponding to DGS region and the 7q11.23 loss associated with Williams-Beuren syndrome critical region were also seen in the 872 affected controls without CVMs, and were thus excluded after comparative analysis.
We then evaluated an independent cohort of 511 subjects with CVMs plus ECAs (BCM2). Of the 55 CNVs detected in the BCM1 cohort, 16 were observed in the BCM2 cohort with significant overlap (Table 2) . These 16 variants, absent in the primary controls (n ¼ 511), were also absent in the second control set (n ¼ 2011) and were validated by FISH studies using BAC clones or long-range PCR (Supplementary Figures 5 and 6 ). None of these 16 variants, including the inherited events, were found to be present in the healthy 2024 pediatric subjects from CHOP Control (phs000199.v1.p1) assayed using an independent SNP array platform.
Of the 16 loci, 12 (75%) were novel, including 16q24.3 loss of ANKRD11, 5p13.2 gain encompassing C50orf42, NUP155 and WDR70, and 2q31.3-q32.1 loss including SSFA2, PPP1R1C, PDE1A and 13q32.3-q33.1 loss. The known genomic disorders including 8p23.1 loss encompassing GATA4 and 22q11.1-q11.21 gain corresponding to CES region were also observed in the replication set, with none of the 2011 controls harboring these CNVs. Interestingly, the rate at which CNVs from cases in the BCM2 cohort overlapped the 55 CNVs from the BCM1 cohort was significantly greater among cases than for controls (odds ratio ¼ 1.683; 95% CI, 1.23-2.27; P ¼ 0.0008634 for CNVs; as well as at the level of individual subjects, odds ratio ¼ 1.972; 95% CI, 1.367-2.8159; P ¼ 0.0002321, scoring subjects as positive when they have at least one CNV overlapping the 55 variants). This result remains significant even when excluding the two segmental calls from chromosome 8, including the GATA4 gene (odds ratio ¼ 1.588; 95% CI, 1.153-2.163; P ¼ 0.0049 for CNVs; odds ratio ¼ 1.8159, 95% CI, 1.24-2.62; P ¼ 0.001728 for individual subjects).
Combining the results from the two groups involving 714 CVM cases (BCM1 and BCM2 groups), we identified 16 CNV regions, present in two or more cases and absent in 2883 controls. The most significant variant observed in the affected was at the 22q11.21 locus, involving 705-kb gain (CECR1) within the CES region (MIM #115470), seen in 4/714 cases and 0/2883 controls, and 16q24.3 de novo loss, observed in 4/714 cases and 0/2883 controls. The 8p23.1 loss (including GATA4 and 25 other genes) was observed in 3/714 cases and 0/2883 controls. Although the CES region gain and GATA4 loss on 8p23.1 are known to be associated with CVMs, loss of 16q24.3 region has not previously been described in association with structural cardiac defects.
To precisely map the deletion breakpoints for 16q24.3 CNV in these cases, genome-wide analysis for DNA copy number alterations was performed using NimbleGen array HG18 WG_CGH_v1 with 385 000 oligonucleotide probes. Breakpoint mapping was performed using long-range PCR (Supplementary Methods). In subject 7658 with a 245-kb deletion with AVSD, the proximal breakpoint of the deletion mapped at 87 853 995 within AluJb and the distal breakpoint at 88 138 377 with an 'A' insertion, likely because of non-homologous end joining (NHEJ) (Figure 1 ). In subject 0340 with septal defect, the proximal breakpoint of the B1.5-Mb deletion mapped within poly T-rich tract between 86 406 011 and 86 406 037 and the distal breakpoint mapped within poly A tract between 87 962 518 and 87 962 533. In subject 0585 with a 2-Mb deletion and AVSD defect, the proximal and the distal breakpoints mapped within the SINE/Alu repeats at 86 051 611 and 88 133 224, respectively. In subject 4535 with septal defect, the proximal breakpoint of the smallest 139-kb de novo deletion mapped between 87 822 867 and 87 862 929 at the 3 0 end of ANKRD11 and the distal breakpoint mapped between 88 001 859 and 88 011 936 within intron 2 of this gene. Subject 2779 with conoventricular VSD and supravalvular pulmonic stenosis was found to have a 1.8-Mb deletion just outside the region of the overlap observed in these four cases. The heterozygous loss found in the four unrelated individuals with overlapping intervals was de novo in all cases. These results are consistent with a strong association of 16q24.3 segmental loss with a syndromic form of CVMs. Some of the other novel loci found in cases included 5p13.2 gain and 13q32.3-q33.1 loss that were observed in 3/714 cases and 0/2883 controls. Other rare CNVs that were observed in 2/714 cases and 0/ 2883 controls included de novo loss of 1q44 and 2q31.3-q32.1 ( Table 3 ). The range of cardiac defects was highly diverse and encompassed all major classes of malformations, including LVOTOs, AVSDs, RVOTOs, conotruncal, APVR, heterotaxy, septal and complex defects. We also identified CNVs in regions previously implicated in CVMs (DECIPHER syndromes), such as 17p13.3 loss (Miller-Dieker lissencephaly syndrome), 8p23.1 deletion syndrome (including GATA4) and 22q11.1-q11.21 gain (CES region). These regions are represented in Table 4 .
There were an additional 2860 segmental events found in controls that overlapped events in the cases, involving 232 non-overlapping genomic segments; there were 575 segmental events involving 226 non-overlapping genomic segments found in the controls but absent from the cases. Overall, there were 38 cases with the 16 CNVs shared by the BCM1 and BCM2 cohorts. Both parental samples were available for further studies in 20/38 of these cases. Of these, 18 were found to be de novo (Supplementary Figures 5 and 6 ) and 2 were inherited. The 152-kb gain involving 11p14.2 in one case and the 971-kb loss of 4q33-q34.1 in another individual were both found to be inherited. Echocardiographic studies were not performed in the carrier parents and we cannot exclude subclinical morphologic abnormalities or anatomic variants in these individuals.
Protein-interaction network
To test the hypothesis that the rare inherited and de novo recurrent CNVs within the CVM plus ECA cohort are enriched for genes encoding proteins that directly interact with proteins known to be required for normal cardiac development, we selected 276 proteins from Gene Ontology cardiac development categories (Supplementary Tables 3 and 4 ) and identified protein-protein interactions in the Human Protein Reference Database (HPRD) that involved any of the proteins encoded within the candidate CNVs from our study (Supplementary Methods). We found that within this network, which contained a total of 234 connections, 11 of the candidate proteins have at least one connection with a human cardiac-specific protein (Supplementary Figure 7) . Interactions were noted for calmodulin-binding transcription activator, CAMTA2 with NKX2-5; CRK with CRKL and ERBB4; SOX7 with SMAD7 and SMAD5; NEIL2 and PELP1 with EP300; ARRB2 with DVL2, OXYR, and TGFBR3 and GATA4 with NKX2-5, SRF, TBX5, EP300, HAND2 and FOG2 (Supplementary Table 5 ).
Haploinsufficiency score analysis
As an additional study, to assess the developmental relevance of the variants identified in this study, we tabulated the haploinsufficiency scores compiled by Huang et al. 29 for the genes within the 16 identified regions. We found that the genes within these variants scored higher than would be expected by chance (Wilcoxon test P-value Po5 Â 10 À5 ). A graphic representation of these results is presented in Supplementary Figure 8 . The high haploinsufficiency score for these regions further support our findings that the variants identified in our study are more likely to be pathogenic and are functionally relevant.
DISCUSSION
This study describes 16 rare non-recurrent structural variants, 450 kb in length, present in individuals with CVMs plus ECAs, and not observed in those without CVMs. Several published reports have examined smaller cohorts of patients with complex clinical presentations and described non-recurrent contiguous gene deletion syndromes contributing to CVMs, including 1p36 monosomy, 30 15q26 deletion, [31] [32] [33] [34] [35] Wolf-Hirschhorn syndrome (4p16.3 deletion), 36 Cri-du-chat syndrome (5p15.2 monosomy), 37 Miller-Dieker lissencephaly syndrome (17p13.3 deletion) 38 and 17q23.1q23.2 microdeletion syndrome. 18 Examples where such an approach was successful in identifying specific dosage-sensitive genes include JAG1 in Allagile Figure 1 Variable de novo (DN) deletions of 16q24.3 observed in multiple subjects with CVMs and ECAs. Five subjects with facial dysmorphisms, developmental delay, septal and AVSD defects are shown to have variable-size 16q24.3 microdeletions. In subject 7658, the proximal breakpoint of the deletion maps within AluJb and the distal breakpoint has an 'A' insertion, likely mediated by NHEJ. In subject 0340, the proximal and the distal breakpoints map within poly T-rich tracts. In subject 0585, the proximal and the distal breakpoints map within the SINE/Alu repeats. syndrome, 39 the LIS1 gene in Miller-Dieker lissencephaly syndrome 40 and TAB2 haploinsufficiency in 6q24-q25 deletion. 41 Using the affected cohort for comparison in our study provides a potentially useful tool for defining subregions affected by genomic disorders that may be causally associated with CVMs. Although it is unlikely that any significant CVM was present in the controls who were evaluated clinically but did not have imaging studies, such occurrences would only reduce power and would not lead to false-positive associations in our analysis. One of the most significant loci enriched in the CVM cohort in our study is the de novo copy number loss of 16q24.3. The phenotype of subject 0585 with AVSD was previously included in the description by Willemsen et al 42 of four individuals with autism spectrum disorder, facial dysmorphisms and brain abnormalities. Mutations in the ANKRD11 gene within this 16q24.3 interval have been described in patients with KBG syndrome, characterized by intellectual disability, skeletal malformations and macrodontia. 43 Congenital heart defects including VSD, partial atrioventricular canal defect and stenosis of the left pulmonary artery have also been reported in some patients with KBG syndrome. [44] [45] [46] Rare microdeletions involving ANKRD11 and the flanking genes ZNF778 and CDH15 were observed most frequently in our CVM cohort. The 2-Mb deletion in patient 0585 is mediated by Alu repeats; however, most deletions observed in this region are non-recurrent and are not mediated by segmental duplications. The individuals in our study also have ECAs with neurocognitive deficits and facial dysmorphisms (Table 2) , as described in other studies. 42, 47 CES caused by dup 22q11 is frequently associated with heart defects, particularly total anomalous pulmonary venous return or tetralogy of Fallot. 48 Although the critical region responsible for CVM has been ill-defined in children affected with CES, Riazi et al. 49 have shown that overexpression of CECR1 causes heart defects in mice, including ASD. Our analysis identified a 705-kb region within this genomic interval that showed copy number gain in 4/714 cases and 0/2883 controls. These cases define a region that includes the CECR1 gene and other genes such as CECR5, CECR4, CECR2, SLC25A18, ATP6V1E1, BCL2L13, BID and MICAL3. The fact that CVMs occurred in all these cases suggests that genes within this narrowed interval contribute to CVMs observed in CES. Parental samples were available for 2/4 cases and both were found to be de novo by FISH analyses (Supplementary Figure 6) . The 5p13.2 gain involving the NUP155 and WDR70 genes was observed in 3/714 cases and none in controls. Parents were not available for further analysis in these cases.
We observed two cases, affected with APVR and LVOTO respectively, with de novo deletion of 2q31.3-q32.1. This region encompasses two genes, PPP1R1C and PDE1A. PDE1A, phosphodiesterase 1A, is calmodulin dependent, expressed in brain and heart 50 and has been shown to regulate cardiac hypertrophy in animal model. 51 Deletion on 13q32.3-q33 was observed in three individuals, two with septal defects and one with complex CVM phenotype. NALCN, a neuronal voltage-independent nonselective cation channel gene within this interval, is known to be expressed in heart. 52 Non-recurrent variable deletions of 17p13.3 are associated with Miller-Dieker lissencephaly syndrome, responsible for lissencephaly in the affected individuals. Although cardiac abnormalities including PDA and septal defects are described in a subset of these cases, no cardiac-specific critical region has been delineated within the larger 17p13.3 region in this syndrome. In our study, septal defects were observed in both individuals with the de novo non-recurrent loss of 17p13.3. The 1.4 Mb enriched region within this region (2/714 cases and 0/2883 controls) includes two candidate genes, PELP1 and CAMTA2, calmodulin-binding transcription activator 2. CAMTA2 is preferentially expressed in heart and brain and acts as a coactivator of Nkx2-5. 53 Although point mutations in CAMTA2 have not yet been described in humans, the gene has been shown to be necessary for maximal hypertrophic response to stresses in mice. 53 The causal role of CAMTA2 in enhancing the ability of Nkx2-5 to activate the ANF promoter 53 and the enrichment of the 17p13.3 CNV in cases support the involvement of this gene in human cardiac development.
Our protein-interaction network analysis identified direct interactions of several of the candidate genes within the 16 structural variants with the annotated human cardiac genes. The variant on 8p23.1 includes SOX7 in addition to GATA4. SOX7 is a transcription factor, which is essential for cardiac development in Xenopus, 54 and has been shown to have direct interactions with both SMAD7 and SMAD5, from our HPRD network analysis. Two of the candidate genes, NEIL2 (expressed in the heart) 55 and PELP1, directly interact with the protein responsible for Rubinstein-Taybi syndrome (RSTS), EP300. 56 Approximately one-third of the individuals with RSTS (MIM #180849) have an associated CVM. Our data suggest that the biological mechanisms underlying the cardiac phenotype in many of these individuals may have a unifying basis, likely affecting common developmental pathways. More extensive studies and further analyses of the CNVs are required to substantiate this resolutely.
A review of CNVs in relatively large studies of CVMs 13, 22, 57, 58 showed few subjects with larger segmental aneusomies overlapping the 16 structural variants observed in our study. In a study of 60 individuals with CVMs and ECAs, Thienpont et al. 13 described one subject with a derivative chromosome 13 with TOF and microcephaly. The smaller 641-kb variant on 13q32.3-q33 in our study overlaps this region described in that study. Similarly, intersecting the 1q44 variant in our study encompassing 126 kb, a large 12.3-Mb deletion of 1q44 was described in another patient with AVSD and an unbalanced chromosomal translocation by Richard et al. 58 However, most CNVs described in these reports are unique to respective studies.
One limitation of our study is that the analysis is insensitive to copy number variants that may be associated with other developmental phenotypes in which the penetrance of the cardiac phenotype is low. A locus may be associated with CVMs, but because of incomplete penetrance will not be ascertained in this study. Nevertheless, the strength of using this approach is the specificity of the CNV association with cardiac malformations.
In summary, our results show that 16q24.3 de novo loss is observed in individuals with CVMs. A number of genes, known or suspected to be involved in cardiogenesis, have been brought to light with regard to their roles in cardiac malformation in ECA cases, such as SOX7 on 8p23.1 and PDE1A on 2q31.3q32.1. The study provides insight into the cardiac-specific critical regions of some of the well-established genomic disorders of CVMs including duplication within the CES region and deletions associated with 8p23.1 and 17p13.3 genomic regions.
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